

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4367148

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST
CONVEYING PARTY DATA	
Name	Execution Date
INTERLEUKIN GENETICS, INC.	04/13/2017
RECEIVING PARTY DATA	
Name:	HORIZON TECHNOLOGY FINANCE CORPORATION
Street Address:	312 FARMINGTON AVENUE
City:	FARMINGTON
State/Country:	CONNECTICUT
Postal Code:	06032
PROPERTY NUMBERS Total: 15	
Property Type	Number
Patent Number:	6524795
Patent Number:	7820383
Patent Number:	6706478
Patent Number:	6268142
Patent Number:	6558905
Patent Number:	7723028
Patent Number:	8105775
Patent Number:	8101360
Patent Number:	9347090
Application Number:	12621201
Application Number:	15233122
Application Number:	13222486
Application Number:	15144263
Application Number:	15404733
Application Number:	62445395
CORRESPONDENCE DATA	
Fax Number:	(860)676-8655
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	lucia@horizontechfinance.com

Correspondent Name: HORIZON TECHNOLOGY FINANCE
Address Line 1: 312 FARMINGTON AVENUE
Address Line 2: ATTN: LEGAL DEPARTMENT
Address Line 4: FARMINGTON, CONNECTICUT 06032

NAME OF SUBMITTER: ERIC S. DARMOFAL

SIGNATURE: /s/Eric S. Darmofal

DATE SIGNED: 04/13/2017

This document serves as an Oath/Declaration (37 CFR 1.63).

Total Attachments: 3

source=Grant of Security Interest Patents (4-13-17) (Interleukin)#page1.tif

source=Grant of Security Interest Patents (4-13-17) (Interleukin)#page2.tif

source=Grant of Security Interest Patents (4-13-17) (Interleukin)#page3.tif

GRANT OF SECURITY INTEREST
PATENTS

THIS GRANT OF SECURITY INTEREST, dated as of April 13, 2017, is executed by INTERLEUKIN GENETICS, INC., a Delaware corporation with an address of 135 Beaver Street, Lexington, MA 02452 ("Debtor"), in favor of HORIZON TECHNOLOGY FINANCE CORPORATION, a Delaware corporation with an address of 312 Farmington Avenue, Farmington, Connecticut 06032 ("Secured Party").

A. Pursuant to a certain First Amendment of Venture Loan and Security Agreement, dated as of August 1, 2016 (the "Agreement") by and between Debtor and the Secured Party, the Secured Party has agreed to extend credit to Debtor upon the terms and subject to the conditions set forth therein;

B. Debtor owns the patents and/or applications for patents, more particularly described on Schedules 1-A and 1-B annexed hereto as part hereof (collectively, the "Patents");


C. Pursuant to the Agreement, Debtor has granted to Secured Party a security interest in all right, title and interest of Debtor in and to the Patents, together with any reissue, continuation, continuation-in-part or extension thereof, and all proceeds thereof (the "Collateral"), to secure the prompt, full and complete payment of the Obligations (as defined in the Agreement) and to secure the prompt, full and complete performance of the Debtor's covenants and duties under each of the Loan Documents (as defined in the Agreement) (other than the Warrants (as defined in the Agreement));

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, Debtor does hereby further grant to Secured Party a security interest in the Collateral to secure the prompt, full and complete payment of the Obligations and to secure the prompt, full and complete performance of the Debtor's covenants and duties under each of the Loan Documents (other than the Warrants).

Debtor does hereby further acknowledge and affirm that the rights and remedies of Secured Party with respect to the security interest in the Collateral granted hereby are more fully set forth in the Agreement, the terms and provisions of which are hereby incorporated herein by reference as if fully set forth herein.

IN WITNESS WHEREOF, Debtor has caused this instrument to be executed as of the day and year first written above.

INTERLEUKIN GENETICS, INC.

By: 
Name: MARK CARBEAU
Title: CEO

SCHEDULE 1-A TO GRANT OF SECURITY INTEREST
PATENTS

Patent	Registration Number	Registration Date
DIAGNOSTICS FOR CARDIOVASCULAR DISORDERS	6,524,795	2/25/2003
METHOD FOR DIAGNOSING MYOCARDIAL INFARCTION	7,820,383	10/26/2010
DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH AN IL-1 INFLAMMATORY HAPLOTYPE	6,706,478	3/16/2004
DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH AN IL-1 INFLAMMATORY HAPLOTYPE	6,268,142	7/31/2001
DIAGNOSTICS AND THERAPEUTICS FOR OSTEOPOROSIS	6,558,905	5/6/2003
DIAGNOSTICS AND THERAPEUTICS FOR OSTEOPOROSIS	7,723,028	5/25/2010
IL-1 GENE CLUSTER AND ASSOCIATED INFLAMMATORY POLYMORPHISMS AND HAPLOTYPES	8,105,775	1/31/2012
IL-1 GENE CLUSTER, INSULIN RESISTANCE AND CORONARY ARTERY DISEASE ASSOCIATED POLYMORPHISMS AND HAPLOTYPES AND METHODS OF USING SAME	8,101,360	1/24/2012
METHOD FOR DETERMINING SEVERITY AND PROGRESSION OF PERIODONTAL DISEASE	9,347,090	5/24/2016

SCHEDULE I-B TO GRANT OF SECURITY INTEREST

PATENT APPLICATIONS

Patent Application	Application Number	Application Date
GENETIC MARKERS FOR WEIGHT MANAGEMENT AND METHODS OF USE THEREOF	12/621,201	11/18/2009
DETECTING GENETIC PREDISPOSITION TO OSTEOARTHRITIS ASSOCIATED CONDITIONS	15/233,122	8/10/2016
METHODS OF PREDICTING OSTEOARTHRITIS	13/222,486	8/31/2011
METHOD FOR DETERMINING SEVERITY AND PROGRESSION OF PERIODONTAL DISEASE	15/144,263	5/2/2016
METHODS FOR PREDICTING RESPONSE TO TREATMENT	15/404,733	1/12/2017
METHODS AND KITS FOR TREATING CARDIOVASCULAR DISEASE	62/445,395	1/12/2017